| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| Bloomberg ticker | FPH NZ |
| ISIN code | NZFAPE0001S2 |
| Industry group | Healthcare |
| Aligned with SDGs |
Fisher & Paykel Healthcare manufactures, designs, and markets medical devices for respiratory care, acute care, and treatment of obstructive sleep apnoea. The company operates through two segments: Hospital and Homecare. It provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. In addition, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, data management products, humidifiers, and accessories.
The company is mainly active in North America (45% of revenues), Europe and Asia-Pacific. The company has ca. 7,000 employees and is headquartered in Auckland, New Zealand.
Investment rationale
Fisher & Paykel provides lifesaving treatments and contributes to better quality of life (in the case of treating sleep apnoea). The company delivers a key treatment (nasal high flow therapy) for adults and babies at a time when they are most vulnerable. Neonatal respiratory distress syndrome is the leading cause of death in premature infants. The company also provides oxygen therapy for adults and devices to control sleep apnoea. In July 2019, The Lancet Respiratory Medicine journal estimated that 936 million adults aged 30–69 years (men and women) have mild to severe obstructive sleep apnoea (OSA). This figure is nearly 10 times greater than the World Health Organization’s 2007 estimate of more than 100 million. In addition, 3% of all children suffer from OSA. Complications that make sleep apnoea a serious medical condition include daytime fatigue, high blood pressure or heart problems. It is a growing medical issue with a clear negative impact on quality of life.
In total 99% of the revenues of the company is aligned with the Well-being transition. The contribution to the Well-being transition comes from 99% of revenues related to the impact objective Healthcare.